Ms. Colleen Fuller at the Health Committee

I think they will strengthen the ability of the prices review board to ensure that the introductory price on drugs is fairer, so my answer is yes.

I also want to point out that the mandate of the prices review board is to basically, as you say, protect consumers from the impact of extended patents. There is a relationship between the patent period and the exposure of Canadians to unfair pricing.